Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Apr;29(4):770-5.
doi: 10.1038/leu.2014.216. Epub 2014 Jul 9.

Management of older or unfit patients with acute myeloid leukemia

R B Walter  1 , E H Estey  2
Affiliations
Review

Management of older or unfit patients with acute myeloid leukemia

R B Walter et al. Leukemia. 2015 Apr.

Abstract

Acute myeloid leukemia (AML) is primarily a disease of older adults, for whom optimal treatment strategies remain controversial. Because of the concern for therapeutic resistance and, in particular, excessive toxicity or even treatment-related mortality, many older or medically unfit patients do not receive AML-directed therapy. Yet, evidence suggests that outcomes are improved if essentially all of these patients are offered AML therapy, ideally at a specialized cancer center. Medical fitness for tolerating intensive chemotherapy can be estimated relatively accurately with multiparameter assessment tools; this information should serve as basis for the assignment to intensive or non-intensive therapy. Until our accuracy in predicting the success of individual therapies improves, all patients should be considered for participation in a randomized controlled trial. Comparisons between individual trials will be facilitated once standardized, improved response criteria are developed, and standard treatment approaches have been defined against which novel therapies can be tested.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest

The authors declare no competing financial interests.

Figures

Figure 1
Figure 1. Incidence and Mortality of AML
Surveillance, Epidemiology, and End Results (SEER) Cancer Registry estimates of incidence and mortality of AML in the U.S. (A) Age-specific incidence rates, SEER 18 areas, 2007–2011. Rates are given per 100,000 and are age-adjusted to the 2000 U.S. Standard Population. (B) 5-year relative survival for men and women of all races, SEER 18 areas, 2004–2010.
Figure 2
Figure 2. Life Expectancy of Older Adults
U.S. Social Security Administration estimates of the average remaining number of years expected prior to death for man or woman of that exact age, born on January 1, using the mortality rates for 2009 over the course of his/her remaining life in the Social Security area population (period life table).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Alibhai SMH, Leach M, Minden MD, Brandwein J. Outcomes and quality of care in acute myeloid leukemia over 40 years. Cancer. 2009;115(13):2903–2911. - PubMed
    1. Burnett AK. Treatment of acute myeloid leukemia: are we making progress? Hematology Am Soc Hematol Educ Program. 2012;2012:1–6. - PubMed
    1. Juliusson G, Lazarevic V, Hörstedt AS, Hagberg O, Höglund M. Acute myeloid leukemia in the real world: why population-based registries are needed. Blood. 2012;119(17):3890–3899. - PMC - PubMed
    1. Juliusson G, Antunovic P, Derolf Å, Lehmann S, Möllgård L, Stockelberg D, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood. 2009;113(18):4179–4187. - PubMed
    1. Oran B, Weisdorf DJ. Survival for older patients with acute myeloid leukemia: a population-based study. Haematologica. 2012;97(12):1916–1924. - PMC - PubMed

Publication types

Substances